Optimized expression of HPV 52 L1 in yeast

Details for Australian Patent Application No. 2005230907 (hide)

Owner Merck Sharp & Dohme Corp.

Inventors Schultz, Loren D.; Bryan, Janine T.; Brownlow, Michelle K.; Jansen, Kathrin U.

Agent Spruson & Ferguson

Pub. Number AU-B-2005230907

PCT Pub. Number WO2005/097821

Priority 60/555,926 24.03.04 US

Filing date 18 March 2005

Wipo publication date 20 October 2005

Acceptance publication date 19 May 2011

International Classifications

C07K 14/025 (2006.01) Peptides having more than 20 amino acids

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 7/04 (2006.01) Viruses, e.g. bacteriophages - Inactivation or attenuation

Event Publications

19 October 2006 PCT application entered the National Phase

  PCT publication WO2005/097821 Priority application(s): WO2005/097821

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

19 May 2011 Application Accepted

  Published as AU-B-2005230907

15 September 2011 Standard Patent Sealed

11 October 2012 Alteration of Name

  The name of the patentee has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005230915-Compounds and methods for treating dyslipidemia

2005230902-Non-imidazole heterocyclic compounds as histamine H3-receptor ligands